+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 78 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating BLU-5937, an oral drug, in adults with refractory chronic cough, including unexplained chronic cough, in a randomized, double-blind, placebo-controlled Phase 3 study. The main goal is to assess how BLU-5937 affects 24-hour cough frequency over 24 weeks. This study also monitors safety by tracking adverse events and changes in various health parameters during the treatment period. Participants are randomly assigned to one of three groups BLU-5937 25 mg twice daily, BLU-5937 50 mg twice daily, or a matching placebo taken twice daily. The treatment lasts for 24 weeks, and participants receive their assigned oral medication regularly throughout this time. The study uses a parallel-arm design and includes an extension in China. During the study, participants undergo assessments including cough frequency measurement, vital signs, blood tests for hormones and chemistry, hematology, and ECGs at baseline and Week 24. Researchers also evaluate cough severity and quality of life using questionnaires. Safety is closely monitored by recording adverse events, treatment discontinuations, and laboratory changes. The total participation duration is 24 weeks, with follow-up assessments at specified intervals.

Age: 18Years - 80YearsAll GendersPhase 3
38 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are conducting a large-scale, multicenter, prospective study to understand ischemic stroke better. The study focuses on collecting various biological samples like blood, feces, and urine from patients diagnosed with ischemic stroke to identify biomarkers linked to the condition. By combining demographic data, clinical indicators, imaging results, and biomarker information, the team aims to create models for risk assessment, early warning, and predicting patient outcomes. The study also seeks to identify key genes and explore related signaling pathways associated with ischemic stroke. Participants receive standard care, which may include intravenous thrombolysis with alteplase administered within the appropriate time window after stroke onset. The study groups include patients categorized based on prognosis as those with favorable or unfavorable outcomes. This observational study tracks patients over time without assigning specific treatments beyond usual care. Participants will undergo regular follow-up assessments, including monitoring cerebrovascular events and evaluating modified Rankin Scale scores three months after stroke onset. Various biological samples are collected to support biomarker analysis. The study involves ongoing data collection on clinical, imaging, and biological parameters to support the development of predictive models. The total duration and specific visit schedules vary by participant, with long-term follow-up planned under the study protocol.

Age: 18Years +All Genders
1 location
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, immune response, and early clinical effects of BNT3212, both alone and combined with pumitamig, in adults with advanced solid tumors who have exhausted other treatment options. This first-in-human, open-label study includes dose escalation and expansion phases to find the best dose and assess how the treatments work across different tumor types. The study is divided into four parts Part A and Part B focus on BNT3212 as a single therapy, with dose escalation followed by dose expansion in specific tumor types. Parts C and D evaluate the combination of BNT3212 with a fixed dose of pumitamig, again starting with dose escalation and then expansion cohorts. Treatments are given by intravenous infusion, and doses are adjusted to find the maximum tolerated dose and recommended dose for further study. Participants will undergo regular monitoring including safety assessments, blood tests to study drug levels and immune reactions, and imaging to measure tumor response. Researchers will track side effects, treatment interruptions, and response rates over approximately 31 months. The study also measures progression-free and overall survival. Continuous evaluation of safety and clinical data supports participant well-being throughout the trial.

Age: 18Years +All GendersPhase 1Phase 2
17 locations
E

Actively Recruiting

Researchers are studying RC288, a drug being evaluated for its safety, tolerability, and effectiveness in treating locally advanced unresectable or metastatic malignant solid tumors. The study aims to find the highest safe dose and the recommended dose for further testing while assessing how well the drug works at that dose. This is a Phase III clinical trial sponsored by RemeGen Co., Ltd., involving multiple centers. Participants receive RC288 through intravenous infusion. The study includes six predefined dose levels that increase stepwise in Phase I to determine the maximum tolerated or administered dose. In Phase II, the recommended dose is further tested across various cancer types to evaluate safety and effectiveness. Patients continue treatment until they experience unacceptable side effects, disease progression, or meet criteria for withdrawal. During the study, participants undergo regular assessments including imaging to measure tumor responses, evaluations for adverse events, and monitoring of vital organ functions. Researchers will collect data over 24 months on dose-limiting toxicities, side effect severity, and tumor response rates using established criteria. The trial lasts up to approximately four years with ongoing safety monitoring and efficacy assessments throughout.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
14 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of sunvozertinib compared to a placebo as additional treatment after surgery in patients with early-stage non-small cell lung cancer NSCLC who have specific EGFR mutations called exon 20 insertion or PACC mutations. This phase 3 study includes patients who have had complete tumor removal and may or may not have received chemotherapy before. Participants will be randomly assigned to receive either sunvozertinib or a matching placebo taken orally once daily in 21-day treatment cycles. Treatment will continue until disease recurrence, unacceptable side effects, completion of three years of therapy, or other study endpoints such as withdrawal or death. The study is double-blind, meaning neither patients nor researchers know which treatment is given. During the trial, participants will be monitored regularly through evaluations including disease-free survival assessed up to approximately five years after the first patient is enrolled. Safety will be closely watched for up to three years, including tracking adverse events and measuring sunvozertinib levels in the blood. Participants will have surgery recovery and organ function assessed before starting treatment, and follow-up will continue long-term to understand treatment impact.

Age: 18Years +All GendersPhase 3
49 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and lasting effects of a single intravitreal injection of 4D-150 compared to aflibercept in adults with diabetic macular edema DME. The study is a Phase 3, randomized, double-masked, active-controlled trial designed to assess visual acuity changes and disease severity over one year. Participants will be randomly assigned to receive either a single dose of 4D-150 or aflibercept eye injections. The 4D-150 treatment is given once on Day 1, while aflibercept is administered at appropriate visits. The study lasts for 52 weeks, focusing on visual outcomes and the need for additional aflibercept injections after the initial treatments. Throughout the study, participants will undergo regular eye examinations to monitor visual acuity using the Early Treatment Diabetic Retinopathy Study ETDRS scale and assessments of diabetic retinopathy severity. Researchers will also track the number of aflibercept injections needed after Week 4. Safety and durability of the treatments will be closely observed during the one-year follow-up period.

Age: 18Years +All GendersPhase 3
87 locations
P

Actively Recruiting

Researchers are evaluating the preliminary safety and effectiveness of AL8326 tablets combined with Toripalimab in patients who have advanced recurrent or metastatic solid tumors. This open, non-randomized phase IIIa trial aims to find the recommended phase II dose and assess objective remission rates among these patients who have limited treatment options or have experienced progression after standard therapies. The study has two parts Phase 1 involves sequential cohorts receiving AL8326 plus Toripalimab 240 mg in 28-day cycles, with dose escalation based on tolerance. Phase 2a continues treatment with AL8326 administered orally daily at the recommended dose alongside Toripalimab 240 mg given in 21-day cycles. Treatment cycles continue for up to 24 months or until disease progression or unacceptable toxicity. Participants will undergo regular assessments including tumor response evaluations every 2 to 4 cycles depending on the phase, along with safety monitoring and laboratory tests. Outcomes measured include remission rates, duration of remission, disease control, progression-free survival, and overall survival. The study requires participants to comply with follow-up procedures and safety evaluations throughout the treatment and observation periods.

Age: 18Years +All GendersPhase 1Phase 2
15 locations
P

Actively Recruiting

Researchers are studying HLX43 an anti-PD-L1 antibody linked to a potent DNA topoisomerase I inhibitor combined with Serplulimab an anti-PD-1 antibody injection in patients with advanced or metastatic solid tumors, including non-small cell lung cancer. This open-label phase IbII clinical trial aims to find the right dosage and assess the safety, tolerability, and effectiveness of this combination treatment. The study has two parts phase Ib for dose escalation and phase II for dose expansion. Participants will receive different doses of HLX43 plus a fixed 300 mg dose of Serplulimab by intravenous infusion every three weeks. Those with good tolerance and disease control will continue treatment every three weeks until disease progression, intolerable side effects, new anti-tumor therapy start, death, or consent withdrawal. Participants will undergo regular assessments including tumor measurements by RECIST 1.1, PD-L1 expression testing from tumor samples, and monitoring of adverse events. Researchers will evaluate dose-limiting toxicity within 21 days after the first dose, maximum tolerated dose over about 12 months, and overall response rate up to 24 weeks. They will also track survival, disease progression, and safety outcomes throughout the study, which may last over two years.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
3 locations
P

Actively Recruiting

Researchers are evaluating YL201, a drug being studied for men with metastatic castration-resistant prostate cancer mCRPC, in an open-label, multicenter phase II trial in China. The study aims to assess the safety, effectiveness, and how the body processes YL201 in this patient group. This research includes patients who have progressed despite prior hormone therapies and may have received limited chemotherapy. The study is sponsored by MediLink Therapeutics Suzhou Co., Ltd. Participants will receive YL201 through intravenous infusion every three weeks, with dosing schedules varying between once or twice per cycle depending on the group. There are multiple dosing cohorts testing different amounts and frequencies of YL201 to find the best dose for future studies. The trial includes about 100 patients divided into initial groups receiving specific doses and a later group receiving the recommended dose and administration method. During the study, participants will undergo regular assessments including imaging scans to measure tumor response and progression, blood tests to monitor drug levels and side effects, and evaluations of prostate-specific antigen PSA levels. Researchers will track objective response rates, progression-free survival, and safety outcomes over approximately 36 months. Tumor tissue analysis for B7H3 expression and monitoring for adverse events will also be part of the study. Participants must comply with scheduled visits and procedures throughout the trial.

Age: 18Years +MALEPhase 2
24 locations
E

Actively Recruiting

Researchers are investigating the effect of baxdrostat, a drug taken once daily, compared to a placebo on lowering 24-hour average systolic blood pressure SBP in adults with uncontrolled hypertension. This condition means their blood pressure remains high despite using two or more antihypertensive medications from different classes without diuretics. The study is a Phase IIIb, randomized, double-blind, placebo-controlled trial conducted across multiple centers in China. Participants will first go through a screening period lasting up to 4 weeks, followed by a 4-week run-in phase where they take a placebo. After this, they will be randomly assigned to receive either baxdrostat 2 mg or placebo orally once daily for 12 weeks while continuing their background blood pressure medications without dose changes, except in cases of low blood pressure symptoms. Rescue therapy is allowed if blood pressure becomes dangerously high, excluding certain diuretics. After treatment, a 2-week safety follow-up will be conducted. The total participation time is approximately 22 weeks. During the study, participants will have their blood pressure monitored, including ambulatory 24-hour average SBP as the primary outcome at week 12. Other assessments include nighttime and daytime blood pressure, seated blood pressure, and safety monitoring for adverse events, including special focus on potassium and sodium levels. Adherence to medication will be tracked, and safety will be overseen by a dedicated committee. Participants health status will be followed through the end of the study period.

Age: 18Years +All GendersPhase 3
51 locations

1-10 of 78

1